Exploration of Targeted Anti-tumor Therapy (Feb 2023)

Research progress in molecular pathology markers in medulloblastoma

  • Zixuan Zhou,
  • Bingxin Zhu,
  • Qingming Meng,
  • Tong Zhang,
  • Yihao Wu,
  • Rutong Yu,
  • Shangfeng Gao

DOI
https://doi.org/10.37349/etat.2023.00126
Journal volume & issue
Vol. 4, no. 1
pp. 139 – 156

Abstract

Read online

Medulloblastoma (MB) is the commonest primary malignant brain cancer. The current treatment of MB is usually surgical resection combined with radiotherapy or chemotherapy. Although great progress has been made in the clinical management of MB, tumor metastasis and recurrence are still the main cause of death. Therefore, definitive and timely diagnosis is of great importance for improving therapeutic effects on MB. In 2016, the World Health Organization (WHO) divided MB into four subtypes: wingless-type mouse mammary tumor virus integration site (WNT), sonic hedgehog (SHH), non-WNT/non-SHH group 3, and group 4. Each subtype of MB has a unique profile in copy number variation, DNA alteration, gene transcription, or post-transcriptional/translational modification, all of which are associated with different biological manifestations, clinical features, and prognosis. This article reviewed the research progress of different molecular pathology markers in MB and summarized some targeted drugs against these molecular markers, hoping to stimulate the clinical application of these molecular markers in the classification, diagnosis, and treatment of MB.

Keywords